Ceftriaxone susceptibility of oxacillin-susceptible Staphylococcus aureus from patients with prosthetic joint infection

Kerryl E Greenwood-Quaintance; Peggy Kohner; Douglas R Osmon; Abinash Virk; Robin Patel

doi:10.1016/j.diagmicrobio.2015.03.002

Ceftriaxone susceptibility of oxacillin-susceptible Staphylococcus aureus from patients with prosthetic joint infection

Diagn Microbiol Infect Dis. 2015 Jun;82(2):177-8. doi: 10.1016/j.diagmicrobio.2015.03.002. Epub 2015 Mar 21.

Authors

Kerryl E Greenwood-Quaintance¹, Peggy Kohner¹, Douglas R Osmon², Abinash Virk², Robin Patel³

Affiliations

¹ Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905.
² Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, 55905.
³ Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905; Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, 55905. Electronic address: patel.robin@mayo.edu.

PMID: 25842182
DOI: 10.1016/j.diagmicrobio.2015.03.002

Abstract

Ceftriaxone is used to treat oxacillin-susceptible S. aureus (OSSA) prosthetic joint infection (PJI). Susceptibility of ceftriaxone against OSSA has been questioned. Ceftriaxone susceptibility was determined against 100 PJI OSSA isolates. Ceftriaxone MIC90/MIC50 were 8/4 and 4/3μg/mL by broth microdilution and Etest, respectively. Ceftriaxone susceptibility is inferable by oxacillin susceptibility.

Keywords: Ceftriaxone; Oxacillin-susceptible Staphylococcus aureus; Prosthetic joint infection.

MeSH terms

Anti-Bacterial Agents / pharmacology*
Arthritis, Infectious / microbiology*
Ceftriaxone / pharmacology*
Humans
Microbial Sensitivity Tests
Oxacillin / pharmacology*
Prosthesis-Related Infections / microbiology*
Staphylococcal Infections / microbiology*
Staphylococcus aureus / drug effects*
Staphylococcus aureus / isolation & purification

Substances

Anti-Bacterial Agents
Ceftriaxone
Oxacillin